Short answer
Inmune Bio, Inc. (INMB) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). Long-term exclusive cord-tissue supply secured for CORDStrom™ platform through expanded Anthony Nolan collaboration.
Inmune Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Long-term exclusive cord-tissue supply secured for CORDStrom™ platform through expanded Anthony Nolan collaboration
- Anthony Nolan receives 2% royalty on product net sales, capped at £5,000,000 annually
- Additional £400 plus VAT fee per umbilical cord tissue, with CPI-linked increases beginning January 1, 2027
- Company assumes joint and several liability with subsidiary IMB for royalty obligations
- Agreement lasts through 10 years after first commercial sale, subject to termination rights and GMP/HTA compliance requirements
Item 7.01 · Regulation FD Disclosure
- Section 7.01 contains only standard Regulation FD liability and incorporation-by-reference language
- No substantive company disclosure or investor-actionable information provided
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inmune Bio, Inc. 8-K filings
Get the next INMB 8-K as it lands
Follow INMB for push alerts, or ask the research agent what this filing means.